614-864-4919 info@sermonixpharma.com
  • Facebook
  • Twitter
  • Linkedin
  • RSS
  • Facebook
  • Twitter
  • Linkedin
  • RSS
Sermonix Pharmaceuticals
  • About
    • Company Overview
    • Management Team
    • Board of Directors
    • Oncology Steering Committee
    • Partners & Collaborations
  • Breast Cancer
  • Pipeline
  • Lasofoxifene
  • For Patients
    • The ELAINE Study
    • The ELAINE 2 Study
  • News & Media
    • News
    • Media
  • Medical Meetings
  • Contact
Select Page

Sermonix Pharmaceuticals Announces Poster Presentation at the 2021 San Antonio Breast Cancer Symposium

by Sermonix Pharmaceuticals | Dec 13, 2021 | News

Poster describes pre-clinical findings that lasofoxifene alone or in combination with a CDK inhibitor may limit tumor progression in aromatase inhibitor (AI) resistant tumors not resistant due to an ESR1 mutation December 13, 2021 10:00 ET | Source: Sermonix...

Sermonix Pharmaceuticals Closes $40 Million Series A3 Financing Round Led by Perceptive Xontogeny Ventures Fund II

by Sermonix Pharmaceuticals | Nov 16, 2021 | News

Funds will be used to further advance lasofoxifene through late-stage clinical development as a next-generation oral SERM to treat women with increasingly prevalent ESR1 breast cancer mutationsInitial data from both Phase 2 clinical trials is expected in H1 2022...

Sermonix Pharmaceuticals Completes Enrollment of Phase 2 Clinical Trial Collaboration Studying …

by Sermonix Pharmaceuticals | Jun 28, 2021 | News

COLUMBUS, Ohio, June 28, 2021 (GLOBE NEWSWIRE) — Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to treat ESR1-mutated metastatic breast and gynecological cancers, today announced that enrollment has...

Sermonix Pharmaceuticals Announces Breast Cancer Research Publication of Preclinical Lasofoxifene Study in Endocrine-Resistant Breast Cancer

by Sermonix Pharmaceuticals | May 19, 2021 | News

Paper highlights the ability of lasofoxifene to inhibit primary tumor growth and reduce metastases in mouse models, both as monotherapy and in combination with palbociclibStudy results demonstrate potential of lasofoxifene as a next-generation selective estrogen...

Sermonix Pharmaceuticals Project With Huntsman Cancer Institute Researcher to Investigate Potential Effects of Lasofoxifene on ESR1 Mutations in Endometrial Cancer

by Sermonix Pharmaceuticals | Apr 21, 2021 | News

Preclinical effort will examine effect of lasofoxifene on unique endometrial cancer models carrying ESR1 mutations COLUMBUS, Ohio, April 21, 2021 (GLOBE NEWSWIRE) — Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative...
« Older Entries
Next Entries »

Recent Posts

  • Sermonix Shares Two Recently Presented Posters Evaluating ESR1 Mutations in Circulating Tumor DNA From Patients With ER+/HER2- Metastatic Breast Cancer Who Were Treated With Lasofoxifene
  • Sermonix Shares Two Posters at SABCS 2022 on ER+/HER2- Metastatic Breast Cancer Patient Survey About Knowledge of NGS and ESR1 Mutations, Quality of Life Concerns
  • Sermonix Pharmaceuticals Announces Poster Presentation on Phase 1 Ethnobridging Study of Lasofoxifene at the 12th AACR-JCA Joint Conference: Breakthroughs in Cancer Research — Translating Knowledge Into Practice
  • Sermonix Pharmaceuticals Announces Four Abstracts Accepted for Presentation at 2022 San Antonio Breast Cancer Symposium
  • Sermonix Pharmaceuticals Shares Details of First-Ever Known Durable Complete Clinical Response in a Metastatic ER+/HER2- Breast Cancer Patient With an ESR1 Mutation After Prior CDK4/6 Inhibitor Treatment Via Single-Agent Hormonally Based Regimen

Recent Comments

    Archives

    • December 2022
    • November 2022
    • September 2022
    • August 2022
    • June 2022
    • April 2022
    • February 2022
    • December 2021
    • November 2021
    • June 2021
    • May 2021
    • April 2021
    • January 2021
    • December 2020
    • October 2020
    • September 2020
    • July 2020
    • June 2020
    • December 2019
    • September 2019
    • June 2019
    • May 2019
    • April 2019
    • March 2019

    Categories

    • News

    Meta

    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org

    © Sermonix Pharmaceuticals